Harrow Health Stock
Harrow Health, Inc.
Company data
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Country
- United States
- CEO
- Mark L. Baum
- Employees
- 373
- Market cap
- $1 B
- IPO
- 28/09/2007
Harrow Health, Inc. operates as a healthcare enterprise with a specialized focus on ophthalmic solutions. The company's portfolio includes the ImprimisRx segment, which is dedicated to ophthalmology outsourcing and pharmaceutical compounding, and DEXYCU, a product utilized for managing post-operative inflammation.…
Company description based on the data provider's company data, AI-assisted, created on 17/10/2026. Not investment advice.
Harrow Health stock: price history
1D
-5.1%
1W
-7.1%
1M
-20.3%
6M
-34.3%
YTD
-44.3%
1Y
-28.1%
2Y
-50.2%
5Y
+175.8%
10Y
+785.7%
Next earnings date
Next earnings date
09/11/2026 (in 23 days)
Volatility around earnings
~11% weaker price swings than usual
Pattern chart
Pattern detected by the Market Jury detector vdouble-bottom-top-v1.0 on 13/10/26. Not a buy or sell signal.Beta
What does this mean?
Double top
BearishThe price failed at a similar high twice, with a pullback in between. This M-shaped pattern is a classic reversal signal from an uptrend into a downtrend.
Chart patterns are a purely technical signal derived from price action. At Market Jury they do not feed into the agents' buy or sell decisions, they are supplementary information only.
Harrow Health stock scores
- Valuation
Visible after free registration
- Trend
Visible after free registration
- Quality
Visible after free registration
- Dividend
Visible after free registration
- Growth
Visible after free registration
- Insider
Visible after free registration
- Earnings
Visible after free registration
- Revisions
Visible after free registration
- Sentiment
Visible after free registration
- Short Pressure
Visible after free registration
Register for free
Unlock all 11 scores
- 5 credits free on registration
- Access to virtual portfolios and watchlist
- No credit card, no payment details needed
- No subscription, no minimum term
- Our own servers in Germany, no US cloud
Deterministically calculated from financial metrics, not investment advice. Updated nightly, last on 21/08/2026.
Ask the agents about Harrow Health
Analyst assessment of Harrow Health
PRICE TARGET LOW
US$45.00
CONSENSUS
US$66.50
MEDIAN
US$66.50
PRICE TARGET HIGH
US$88.00
0
STRONG BUY
10
BUY
0
HOLD
0
SELL
0
STRONG SELL
10
TOTAL · Buy
As of: 07/10/2026
Harrow Health stock metrics
P/E
-27.49
P/B
67.03
EV/EBITDA
110.8
RETURN ON EQUITY
-113.6%
NET MARGIN
-24.4%
DEBT/EQUITY
19.79
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
77.2%
FLOAT SHARES
28,929,749
AVG. DAILY VOLUME (30D)
617,524
Insider transactions (SEC)
Shojaei Amir
Shojaei Amir
SILVERNAIL LAUREN P
Graves Adrienne L
BOLL ANDREW R.
Attention
Price since yesterday: -5.1%
Search (Google Trends)
Institutional holders
Dividends & Stock splits
Comparable stocks
Frequently asked questions about Harrow Health stock
What does Harrow Health do?
Harrow Health, Inc. is a company in the Healthcare sector, Drug Manufacturers - Specialty & Generic industry, headquartered in United States.
The CEO is Mark L. Baum, the company employs around 373 people.
The IPO was on 28/09/2007; the stock trades on NASDAQ under the ticker HROW.
What do analysts say about Harrow Health stock?
10 analysts rate the stock, the consensus is Buy (as of 07/10/2026).
The average price target is US$66.50, ranging from US$45.00 to US$88.00, with a median of US$66.50.
This is an external assessment, not a statement by Market Jury.
When does Harrow Health report next?
The next earnings date is 09/11/2026.
Around past earnings, price swings were roughly -11% stronger than usual.
Does Harrow Health pay a dividend?
No, Harrow Health currently does not pay a dividend.
Which stocks are comparable to Harrow Health?
Comparable stocks include Zoetis, Viatris, Lantheus Holdings, Amneal Pharmaceuticals, Indivior Pharmaceuticals, Eton Pharmaceuticals, Pacira BioSciences and Amphastar Pharmaceuticals.
How can I get Harrow Health stock analyzed?
Clicking "Analyze stock" lets five strategies assess Harrow Health against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.